New York, July 11, 2024 - PRISM MarketView - CEO Josh Riggs of the molecular diagnostics technology company, Oncocyte (OCX) was featured on the MedTech Guru’s latest podcast episode 247, “Take Advantage of the Moment”. Riggs discusses Oncocyte’s innovative strategies in molecular diagnostic technology and the profound impact of this technology on patient care.
In the episode, MedTech podcast host Thomas Hickey identifies Oncocyte as a market disruptor and compares the company to Yogi Berra and “hitting it where they ain’t”, as it relates to Oncocyte playing in a space where others are not. Riggs explains that Oncocyte’s ability to differentiate themselves in the space allows the company to be flexible, creating substantial margins that can be shared with its customers and partners while still generating an exceptional return for its investors.
Riggs emphasizes that the high value of Oncocyte’s offering lies not merely in the test itself but in the sophisticated algorithm and software that underpin the molecular test, driving significant value creation. Oncocyte’s test can identify transplant rejection 10 months ahead of protocol, providing a remarkable competitive advantage.
“There’s demand for this type of testing, and there’s demand for access of this technology. And so for us, it’s all commercial execution at this point. And I think the most exciting thing for us will be able to say, how many sites have we brought up and what percentage of that transplant volume have we captured in the US and on a global basis.”
Oncocyte CEO, Josh Riggs
To enjoy the entire MedTech Guru’s “Take Advantage of the Moment” episode, click here.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities